Edesa Biotech (Edesa Biotech) EPS (Diluted) : $-2.64 (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech EPS (Diluted)?

Edesa Biotech's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.54. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.64.

Edesa Biotech's EPS (Basic) for the three months ended in Dec. 2023 was $-0.54. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.64.

Edesa Biotech's EPS without NRI for the three months ended in Dec. 2023 was $-0.54. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.63.

During the past 3 years, the average EPS without NRIGrowth Rate was -58.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 35.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Edesa Biotech's highest 3-Year average EPS without NRI Growth Rate was 71.40% per year. The lowest was -94.60% per year. And the median was 18.05% per year.

Edesa Biotech EPS (Diluted) Historical Data

The historical data trend for Edesa Biotech's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech EPS (Diluted) Chart

Edesa Biotech Annual Data

Trend

Aug14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EPS (Diluted)

Get a 7-Day Free Trial

-3.85

-5.18

-7.70

-8.37

-20.51

Edesa Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-0.89	-0.84	-0.70	-0.56	-0.54

Competitive Comparison of Edesa Biotech's EPS (Diluted)

For the Biotechnology subindustry, Edesa Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edesa Biotech's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's PE Ratio falls into.

Edesa Biotech EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Edesa Biotech's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.374	-	0)	/	0.408
	=	-20.52

Edesa Biotech's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.678	-	0)	/	3.128
	=	-0.54

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.64

Edesa Biotech (NAS:EDSA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Edesa Biotech EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Edesa Biotech (Edesa Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Spy Court, Markham, ON, CAN, L3R 5H6

Website

https://www.edesabiotech.com

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Executives

Stephen Lemieux	officer: Chief Financial Officer	100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter	director, 10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks	officer: President	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Pardeep Nijhawan	director, 10 percent owner, officer: Chief Executive Officer	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes	director, officer: President, CEO, & Director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson	director	3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp	10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse	director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041